Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats

Journal of Pharmacological Sciences

Volumn 111, Issue 3, 2009, Pages 235-243

  Sawamura, Fusae ^a   Kato, Masami ^b   Fujita, Kazuhisa ^b   Nakazawa, Takahiro ^a   Beardsworth, Anthony ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Nihon Bioresearch Inc   (Japan)

Author keywords

Monocrotaline (MCT); Phosphodiesterase 5 (PDE5) inhibitor; Pulmonary artery hypertension (PAH); Survival; Tadalafil

Indexed keywords

CYCLIC GMP; MONOCROTALINE; PHOSPHODIESTERASE V; SILDENAFIL; TADALAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL BLOOD; ARTICLE; CONTROLLED STUDY; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; NONHUMAN; OXYGEN TENSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SURVIVAL RATE;

EID: 73349135641     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09110FP     Document Type: Article

References (41)

1. Primary pulmonary hypertension: executive summary from the World Symposium on Primary Pulmonary Hypertension 1998. Rich S, editor. World Health Organization, 6-10 September 1998, Evian, France.
2. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43: 40S-47S.
3. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
4. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Robin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119-2125.
5. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immuno-deficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212-1217.
6. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25:502-508.
7. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30: 338-344.
8. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48-54.
9. Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs. 2008;68:383-397.
10. Berman Rosenzweig E, Schmitt KA, Garofano R, Barst RJ. Identical twins with primary pulmonary hypertension: beraprost vs epoprostenol. Chest. 2004;125:1157-1160.
11. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
12. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.
13. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69:223-231.
14. Saenz de Tejada I, Angulo Frutos J, Gaudo M, Florio V. Comparative selectivity profiles of tadalafil, sildenafil, and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res. 2002;14:S20-S32.
15. Venugopalan M, Saenz de Tejada I, Angulo J, Gadau M, Martins T, Florio V, et al. Tadalafil (IC351) enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. 8th APSIR Oral Presentations /Asian J Androl. 2002;4 Suppl 1:60.
16. Chang S, Patterson B, Bedding A, Forgue ST, Jewell H, Payne C, et al. Dose-normalized pharmacokinetics of tadalafil (IC351) administered as a single dose to healthy volunteers. 8th APSIR Oral Presentations /Asian J Androl. 2002;4 Suppl 1:61.
17. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006;60:967-975.
18. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334: 930-938.
19. Wharton J, Strange JW, Møller GMO, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105-113.
20. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
21. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
22. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
23. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92:9M-18M.
24. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther. 2006;316:654-661.
25. Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg. 2006;81: 272-278.
26. Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature. 1968; 217:723-728.
27. Hilliker KS, Bell TG, Lorimer D, Roth RA. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension. Am J Physiol. 1984;246:H747-H753.
28. Hilliker KS, Bell TG, Roth RA. Pneumotoxicity and thrombocytopenia after single injection of monocrotaline. Am J Physiol. 1982;242:H573-H579.
29. Mathew R, Zeballos GA, Tun H, Gewitz MH. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res. 1995;30:739-746.
30. Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol. 1981;240: H149-H155.
31. Wilson DW, Segall HJ, Pan LC, Lamé MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22:307-325.
32. Seyfarth T, Gerbershagen HP, Giessler C, Leineweber K, Heinroth-Hoffmann I, Pönicke K, et al. The cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in monocrotalinetreated rats. J Mol Cell Cardiol. 2000;32:2315-2326.
33. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:39-45.
34. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:34-38.
35. 2α, in the rat. Br J Pharmacol. 1997;122:899-905.
36. Mathew R, Gloster ES, Sundararajan T, Thompson CI, Zeballos GA, Gewitz MH. Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. J Appl Physiol. 1997;82:1493-1498.
37. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007;49:1079-1088.
38. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC. Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006;17: 2742-2747.
39. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest. 1991;87:1402-1412.
40. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147.
41. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248.